Cardiome Pharma reviews record revenues in second quarter 2014 Cardiome Pharma Corp. today reported financial outcomes for the second quarter and half a year ended June 30, 2014 donde comprar finasteride en . Amounts, unless specified in any other case, are expressed in U.S. Dollars and in accordance with generally accepted accounting concepts used in america of America . On April 12 All talk about and per share quantities reflect the one-for-five share consolidation that occurred, 2013. Cardiome's financial outcomes for the second quarter and first half a year of 2014 are on the right track with our plan, stated William Hunter, M.D., Cardiome's CEO and president.
Related StoriesDeaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHMEIdentifying obstructive coronary artery disease in women: an interview with Dr. Ladapo, NYU College of MedicineBrain health: how can you reduce cognitive decline? An interview with Heather Snyder, Ph.D. To date, CardioInsight's electrocardiographic mapping system has been employed in over 800 sufferers in multiple centers and multiple arrhythmia types. Outcomes of the studies have generated nearly 100 publications and presentations in peer-examined journals and at worldwide clinical conferences. This includes latest publications in the Journal of the American College of Cardiology and presentations during the 2013 Heart Rhythm Society Scientific Classes describing the Company's recent multi-center, multi-rhythm mapping research.